S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:AMGN

Amgen - AMGN Stock Forecast, Price & News

$245.17
-1.36 (-0.55%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$242.21
$249.96
50-Day Range
$245.17
$286.40
52-Week Range
$214.39
$296.67
Volume
3.07 million shs
Average Volume
2.39 million shs
Market Capitalization
$130.82 billion
P/E Ratio
20.25
Dividend Yield
3.15%
Price Target
$253.94

Amgen MarketRank™ Forecast

Analyst Rating
Hold
2.07 Rating Score
Upside/​Downside
3.6% Upside
$253.94 Price Target
Short Interest
Healthy
1.65% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.13mentions of Amgen in the last 14 days
Based on 81 Articles This Week
Insider Trading
Selling Shares
$159,979 Sold Last Quarter
Proj. Earnings Growth
12.49%
From $17.85 to $20.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

39th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

9th out of 168 stocks

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

The Dow’s Biggest Dividends: Here Are 2023’s Dogs.
Stocking the kitchen and rewarding the team could go a long way in boosting morale.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
StockNews.com Downgrades Amgen (NASDAQ:AMGN) to Buy
Oppenheimer Cuts Amgen (NASDAQ:AMGN) Price Target to $294.00
Amgen (NASDAQ:AMGN) Given New $289.00 Price Target at Cowen
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Amgen (NASDAQ:AMGN) PT Lowered to $253.00
Amgen (NASDAQ:AMGN) Price Target Cut to $258.00
Amgen (NASDAQ:AMGN) Price Target Cut to $275.00
Why Amgen Stock Wilted on Wednesday
Why Amgen Shares Are Falling
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Amgen (AMGN) Surpasses Q4 Earnings and Revenue Estimates
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Ex-Dividend for 12/8 Dividend
11/16/2022
Dividend Payable
12/08/2022
Last Earnings
1/31/2023
Today
2/04/2023
Ex-Dividend for 3/8 Dividend
2/14/2023
Dividend Payable
3/08/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
24,200
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$253.94
High Stock Price Forecast
$294.00
Low Stock Price Forecast
$182.00
Forecasted Upside/Downside
+3.6%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
14 Analysts

Profitability

Net Income
$5.89 billion
Pretax Margin
27.91%

Debt

Sales & Book Value

Annual Sales
$26.32 billion
Cash Flow
$18.12 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
531,125,000
Market Cap
$130.82 billion
Optionable
Optionable
Beta
0.63

Social Links


Key Executives

  • Robert A. BradwayRobert A. Bradway
    Chairman, President & Chief Executive Officer
  • Esteban Santos
    Executive Vice President-Operations
  • Peter H. GriffithPeter H. Griffith
    Chief Financial Officer & Executive Vice President
  • Mike Zahigian
    Chief Information Officer & Senior Vice President
  • David M. Reese
    Executive Vice President-Research & Development













AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 4 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price forecast for 2023?

14 equities research analysts have issued 1 year price targets for Amgen's stock. Their AMGN share price forecasts range from $182.00 to $294.00. On average, they anticipate the company's stock price to reach $253.94 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2023?

Amgen's stock was trading at $262.64 at the start of the year. Since then, AMGN stock has decreased by 6.7% and is now trading at $245.17.
View the best growth stocks for 2023 here
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Tuesday, January, 31st. The medical research company reported $4.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.05. The medical research company had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.77 billion. Amgen had a trailing twelve-month return on equity of 359.47% and a net margin of 24.89%. The company's quarterly revenue was down .1% on a year-over-year basis. During the same period in the previous year, the company earned $4.36 EPS.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Monday, December 12th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $2.13 per share on Wednesday, March 8th. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend is Tuesday, February 14th. This is a boost from the stock's previous quarterly dividend of $1.94.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.15%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 70.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.43% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY 2023 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of $17.40-$18.60 for the period, compared to the consensus EPS estimate of $17.68. The company issued revenue guidance of $26.00 billion-$27.20 billion, compared to the consensus revenue estimate of $26.25 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of retail and institutional investors. Top institutional investors include Edmp Inc. (0.85%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), Bank of Montreal Can (0.19%), New York State Common Retirement Fund (0.18%), Sarasin & Partners LLP (0.18%) and DekaBank Deutsche Girozentrale (0.18%). Insiders that own company stock include David Piacquad, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $245.17.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $130.82 billion and generates $26.32 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $12.11 on an earnings per share basis.

How many employees does Amgen have?

The company employs 24,200 workers across the globe.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 2/5/2023 by MarketBeat.com Staff